Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors

This phase I study aimed to determine tolerability and preliminary efficacy of single‐agent alpelisib (BYL719) in Japanese patients with advanced solid malignancies. The primary objective of the study was to estimate the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of oral al...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, Yuichi, Iwasa, Satoru, Takahashi, Shunji, Saka, Hideo, Kakizume, Tomoyuki, Natsume, Kazuto, Suenaga, Naoko, Quadt, Cornelia, Yamada, Yasuhide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398875/
https://www.ncbi.nlm.nih.gov/pubmed/30588709
http://dx.doi.org/10.1111/cas.13923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398875/
https://www.ncbi.nlm.nih.gov/pubmed/30588709
http://dx.doi.org/10.1111/cas.13923

Ejemplares similares